Diabetic statin users have a lower risk for colorectal cancer than nonusers, report US researchers.

Colorectal cancer is the third most common cause of cancer and second most common cause of death in the USA. It is also particularly prevalent in diabetic individuals.

“Experimental studies indicate a potential cancer prevention effect for statins,” say Hashem El-Serag (Baylor College of Medicine, Houston, Texas) and colleagues. “However, the available epidemiological data are conflicting.”

In this study, the researchers assessed the influence of statin use on risk for colorectal cancer among 30,400 veterans with diabetes. The data were taken from national databases of the Department of Veterans Affairs and Medicare-linked files.

Overall, 6080 diabetic patients with colorectal cancer and 24,320 without the cancer were examined. The cohort members were aged 74 years on average, were 88% Caucasian, and were 99% male.

Filled statin prescriptions (87% simvastatin) were recorded for 49% of cases and 52% of controls. Mean duration of statin use was also lower in cases at 274 versus 296 days for controls.

The team calculated that the presence of a filled prescription for any statin was associated with a significant 12% reduction in risk for colorectal cancer. This association remained significant after adjustment for factors such as diabetes severity, inflammatory bowel disease, cholecystectomy, liver disease, and filled prescriptions for sulfonylurea of aspirin.

However, the significant inverse association was restricted to Caucasian patients suffering from colon cancer (not rectal cancer) who were 65 years or older and who had no previous history of polyps.

Of note, non-statin related cholesterol level and use of triglyceride-lowering medication were not linked to risk for colorectal cancer. In addition, the use of insulin did not significantly affect the influence of statins on colon cancer risk.

El-Serag and co-investigators caution that the reduction in risk observed in this study is small and likely restricted to colon cancer. They emphasize that they did not see “a clear dose??”response or duration??”response relationship between filled statin prescriptions and colorectal cancer risk.”

The results of this study are published in the American Journal of Gastroenterology.

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009

Free abstract

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

You must be logged in to post a comment.